Moderna, Inc. and Merck have reported five-year follow-up results from the Phase 2b KEYNOTE-942 study evaluating intismeran autogene (mRNA-4157 or V940), an investigational individualized mRNA-based neoantigen therapy, in combination with pembrolizumab (KEYTRUDA) in patients with resected high-risk stage III or IV melanoma. The combination demonstrated a 49 percent reduction in the risk of recurrence or
Evolve Orthopedic Partners expands its musculoskeletal platform with four-practice deal in New York. Find out how this model could redefine MSO growth.
Johnson & Johnson (J&J) has presented new pooled data from Phase 3 clinical trials showing that CAPLYTA (lumateperone), used as an adjunctive therapy with antidepressants, significantly improved remission rates in adults with major depressive disorder compared to placebo. The results, highlighted at the 64th Annual Meeting of the American College of Neuropsychopharmacology, indicate nearly double
New study shows neuropathy reversal can restore healing in tissue facing amputation. Find out how Rapid Nexus could reshape wound care.
GSK plc has received regulatory approval from China’s National Medical Products Administration (NMPA) to market Trelegy Ellipta, a once-daily inhaled combination of fluticasone furoate, umeclidinium, and vilanterol, for the treatment of adult patients with uncontrolled asthma. This decision expands Trelegy Ellipta’s label beyond its existing indication in chronic obstructive pulmonary disease (COPD), making it the
Find out how Bridge to Life’s FDA-cleared VitaSmart system could reshape liver transplant workflows in 2026.
CereVasc completes ETCHES trial enrollment for its eShunt device in post-SAH hydrocephalus. Learn what this means for future neurosurgical care.
NeuroSense gains a U.S. patent for PrimeC in Alzheimer’s disease. Find out what it means ahead of key trial results due in early 2026.
Gore’s VIATORR device earns CE mark for 6–10 mm range, enabling tailored TIPS procedures. Find out how this could reshape portal hypertension care.
Trisol’s valve shows early safety and efficacy in high-risk TR patients. Explore what this means for the future of transcatheter tricuspid therapies.